Trial · NCT04096066
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
NCT04096066, Phase 3, Active not recruiting, Fondazione EMN Italy Onlus
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant. Trials, record NCT04096066. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04096066
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
- NCT number
- NCT04096066
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 84 participants, actual
- Lead sponsor
- Fondazione EMN Italy Onlus
- Conditions
- Multiple Myeloma, New Diagnosis Tumor
- Interventions
- Carfilzomib, Lenalidomide, Dexamethasone
- First posted
- 2019-09-19
- Last updated
- 2026-09-21
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Minimal residual disease (MRD) | 5 years | 1\. Minimal residual disease (MRD): unit of measure is not applicable, MRD is expressed as a pure number |
| Primary | Progression-free survival (PFS) | 5 years | 2\. Progression-free survival (PFS): unit of measure is not applicable, PFS is expressed as a pure number |
| Secondary | Rate of drug reduction or drug discontinuation | 5 years | Incidence of dose reduction and drug discontinuation in both treatment arms. |
| Secondary | Cardiovascular assessment | 5 years | Benefit of proper cardiovascular baseline assessment and monitoring during treatment in both treatment arms:to mitigate major cardiovascular adverse event incidence, to prolong duration of treatment, to improve efficacy. |
| Secondary | Rate of dose reduction, drug discontinuation and toxicities | 5 years | Safety as rate of dose reduction, drug discontinuation and toxicities |
| Secondary | Response rate | 5 years | Response rate will include complete response (CR), very good partial response (VGPR) and partial response (PR) using the International Response Criteria. Responders are defined as subjects with at least a PR. |
| Secondary | Progression-free survival 2 (PFS2) | 5 years | Time from randomization to objective tumor progression on next-line treatment or death from any cause. |
| Secondary | Time to progression (TTP) | 5 years | Time to progression will be measured from the date of randomization to the date of first observation of PD, or deaths related to PD. |
| Secondary | Duration of response (DOR) | 5 years | Time between first documentation of response and PD. Responders without disease progression will be censored either at the time of lost to FU, at the time of death due to other cause than PD, or at the end of the study. |
| Secondary | Overall survival (OS) | 5 years | Time between randomization and death. Subjects who die will be censored at time of death as an event, regardless cause of death. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40769686 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04096066
GET https://conductscience.org/api/trials/v1/NCT04096066/registered